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Distal hereditary motor neuronopathy type VII (dHMN-VII) is an autosomal dominant disorder characterized by
distal muscular atrophy and vocal cord paralysis. We performed a genomewide linkage search in a large Welsh
pedigree with dHMN-VII and established linkage to chromosome 2q14. Analyses of a second family with dHMN-
VII confirmed the location of the gene and provided evidence for a founder mutation segregating in both pedigrees.
The maximum three-point LOD score in the combined pedigree was 7.49 at D2S274. Expansion of a polyalanine
tract in Engrailed-1, a transcription factor strongly expressed in the spinal cord, was excluded as the cause of
dHMN-VII.
The peroneal muscular atrophy syndrome, also known
as Charcot-Marie-Tooth disease (CMT [MIM 118200])
is the most common inherited disorder of the peripheral
nervous system, affecting 1 in 2,500 people (Keller and
Chance 1999). The cardinal clinical features are weak-
ness and wasting of the distal limb muscles, hypo- or
areflexia, and pes cavus deformity of the foot. Distal
sensory loss is present in some cases. Three distinct
groups of peroneal muscular atrophy conditions are rec-
ognized: (1) a demyelinating form, hereditary motor and
sensory neuropathy type I (HMSN I or CMT1); (2) an
axonal form, hereditary motor and sensory neuropathy
type II (HMSN II or CMT2); and (3) distal hereditary
motor neuronopathy (dHMN, also known as distal spi-
nal muscular atrophy, or spinal CMT) (De Jonghe et al.
1998).
dHMN accounts for ∼10% of peroneal muscular at-
rophy syndrome (Harding and Thomas 1980). Motor
and sensory nerve conduction velocities are normal, and
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electromyography typically shows features of neurogenic
atrophy, consistent with degeneration of the anterior
horn cell of the spinal cord. On the basis of clinical and
genetic criteria, dHMN is divided into seven subtypes
(Harding 1993). The genes for several dHMN subtypes
and related conditions have been localized (table 1).
However, no causative dHMN genes have thus far been
isolated.
dHMN-VII (MIM 158580) is an autosomal dominant
condition characterized by distal muscular atrophy as-
sociated with unilateral or bilateral vocal cord paralysis.
Young and Harper (1980) first described the condition
in a large Welsh kindred. Other families with similar
phenotypes were subsequently reported (Serratrice et al.
1984; Boltshauser et al. 1989; Pridmore et al. 1992).
We report the localization of the dHMN-VII gene to
chromosome 2q14 by linkage and allelic association
analyses in two families with dHMN-VII, including the
original family, YH1, described by Young and Harper.
Detailed clinical and pathological features of members
of family YH1 have been published elsewhere (Young
and Harper 1980). Permission for the current study was
obtained from the local research-ethics committee, and
all individuals analyzed were reevaluated clinically by
one of the authors (M.M.). dHMN-VII typically pre-
sented in the second decade, with weakness and wasting
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Table 1
Distal Hereditary Motor Neuronopathy Conditions for Which Predisposition Genes Have Been Localized
Disorder Features Inheritancea Locus Reference
dHMN-II Adult-onset distal wasting and weakness AD 12q24.3 Timmerman et al. (1996)
dHMN-V Upper limb predominance;
occasionally pyramidal features AD
7p15 Christodoulou et al. (1995)
dHMN-VI Severe infantile form with respiratory distress AR 11q13-21 Grohmann et al. (1999)
dHMN-VII Adult onset with vocal cord paralysis AD 2q14 Present report
dHMN–Jerash typeb Juvenile onset with pyramidal features AR 9p21.1-p12 Middleton et al. (1999);
Christodoulou et al.
(2000)
Congenital dSMAb,c Congenital nonprogressive dHMN with
contractures AD
12q23-q24 van der Vleuten et al. (1998)
a AD p autosomal dominant; AR p autosomal recessive.
b dHMN–Jerash type and congenital dSMA were not included in the original classification of these disorders by Harding (1993).
c dSMA p distal spinal muscular atrophy, interchangeable with dHMN.
of the small muscles of the hand and thenar eminence.
Subsequently, weakness and wasting of the distal mus-
cles of the lower limbs occurred. All but one affected
individual developed a hoarse voice, which resulted from
unilateral or bilateral vocal cord paralysis. The age of
subjects at vocal cord involvement varied and preceded
the hand changes in some individuals. As muscle wasting
progressed, deep-tendon reflexes were lost, but sensation
remained intact in all cases. Disease progression was
slow and compatible with a normal life span. Motor and
sensory nerve conduction velocities were normal, and
electromyography was suggestive of chronic partial
denervation.
A genomewide linkage search was performed on 10
affected individuals and 3 spouses in family YH1. A total
of 230 microsatellite markers, spaced at 20-cM intervals,
were selected from the ABI PRISM linkage-mapping set
version 2 (Applied Biosystems) and were PCR amplified
using standard protocols. Amplified markers were elec-
trophoresed through 4.5% denaturing polyacrylamide
gels on an ABI 377 DNA sequencer and were analyzed
with GENESCAN and GENOTYPER software (Applied
Biosystems).
dHMN-VII was modeled as an autosomal dominant
trait with a penetrance of 95% by age 20 years. Unaf-
fected individuals aged !20 years were coded as “un-
known.” A disease allele frequency of .0001 and equal
recombination fractions in males and females were as-
sumed. Two-point LOD scores were calculated using the
MLINK program of LINKAGE, and multipoint (three-
point) LOD scores were generated using the VITESSE
program. Marker allele frequencies were estimated from
unrelated individuals from the pedigrees.
In the linkage search, marker D2S112 generated the
highest two-point LOD score, and positive LOD scores
at consecutive markers occurred only at D2S160 and
D2S112 on chromosome 2q14 (table 2). To confirm and
refine the location of the dHMN-VII predisposition
gene, 10 additional markers, spanning a 40-cM region
on chromosome 2q14, were analyzed. DNA from an
additional six unaffected relatives were included in these
analyses. The order and distance from the p-telomere of
the chromosome 2q14 markers are shown in table 3.
Examination of the marker-allele haplotypes, segregat-
ing in affected individuals only, placed the dHMN-VII
gene in a 36-cM region flanked by D2S2216 and
D2S2288 (fig. 1). Meiotic recombinants in unaffected
individuals IV:3 and V:7 refined the dHMN-VII region
to a 20-cM interval flanked by D2S2264 and D2S2215
(fig. 1). The maximum two-point LOD score was 4.21
at D2S275, and the maximum multipoint LOD score
was 5.01 at D2S100.
A second pedigree with dHMN-VII (family P2) was
examined for linkage to chromosome 2q14. The clinical,
pathological, and electrophysiological features in mem-
bers of family P2 were similar to those in members of
family YH1 and have been published elsewhere (Prid-
more et al. 1992). All individuals analyzed in this study
were reevaluated by one of the authors (H.H.). Twelve
microsatellite markers, spanning the 20-cM dHMN-VII
interval defined in family YH1, were analyzed. The
marker haplotypes demonstrated that affected individ-
uals shared a haplotype of marker alleles that was not
present in their unaffected relatives (fig. 2). Positive two-
point LOD scores were observed at all markers with a
maximum two-point LOD score of 2.18 at D2S100 (ta-
ble 2). The maximum multipoint LOD score was 2.25
at D2S2265. At a candidate locus, these values provide
strong evidence in favor of linkage. The disorder in fam-
ily P2 is thus highly likely to be due to mutation of the
dHMN-VII gene on chromosome 2q14.
Scrutiny of the marker haplotypes revealed the dis-
ease-associated alleles in family P2 to be identical to
those segregating in family YH1 for 11 of the 12markers
initially analyzed. This was suggestive of a founder mu-
tation predisposing to the disease in both families. To
1272 Am. J. Hum. Genet. 68:1270–1276, 2001
Table 2





TWO-POINT LOD SCORE AT vp
0 .01 .05 .10 .20 .30
D2S2216:
YH1 3.85 1.23 .56 .30 .11 .04
P2 .95 .93 .83 .70 .47 .26
D2S2209:
YH1 2.02 2.01 1.92 1.75 1.30 .79
P2 .25 .24 .20 .15 .08 .04
D2S2264:
YH1 1.83 1.80 1.67 1.48 1.08 .66
P2 2.12 2.08 1.92 1.71 1.27 .79
D2S274:
YH1 3.66 3.59 3.29 2.91 2.11 1.29
P2 1.79 1.76 1.61 1.42 1.02 .62
D2S293:
YH1 4.06 3.97 3.64 3.22 2.33 1.42
P2 .38 .37 .33 .28 .20 .13
D2S160:
YH1 .95 .91 .75 .56 .25 .06
P2 2.09 2.05 1.89 1.67 1.23 .75
D2S100:
YH1 3.44 3.38 3.11 2.75 2.00 1.21
P2 2.18 2.14 1.98 1.76 1.31 .82
D2S275:
YH1 4.21 4.12 3.79 3.37 2.47 1.53
P2 1.85 1.82 1.67 1.49 1.09 .67
D2S2215:
YH1 2.19 2.20 2.14 1.96 1.46 .88
P2 .21 .20 .17 .13 .07 .03
D2S112:
YH1 2.36 2.37 2.29 2.10 1.56 .94
P2 2.10 2.06 1.90 1.69 1.26 .79
D2S2219:
YH1 1.10 1.13 1.16 1.09 .82 .49
P2 1.68 1.64 1.50 1.32 .94 .56
D2S2288:
YH1 3.85 1.45 .55 .16 .10 .12
P2 .51 .50 .47 .43 .35 .25
Table 3
Microsatellite Marker Alleles Segregating with dHMN-VII in












104 D2S2333 10 6 3.01
111 D2S2216 6 3 2.52
112 D2S2209 1 1 2.60
114 D2S2264a 3 3 4.51
115 D2S274 6 6 6.04
116 D2S2229 6 6 4.27
117 D2S1897 3 3 2.67
118 D2S293 3 3 4.96
120 D2S1890 4 4 3.56
122 D2S160 5 3 .19
124 D2S308 3 6 1.41
125 D2S437 4 5 .03
127 D2S2970 3 5 2.24
128 D2S100 4 4 6.33
129 D2S2265 4 4 1.12
130 D2S2224 1 1 1.92
131 D2S347 12 12 4.05
132 D2S2339 4 4 5.18
132 D2S275 4 4 6.63
132 D2S1273 8 8 2.03
132 D2S1272 11 11 3.19
133 D2S2271 1 1 3.97
133 D2S95 6 6 6.05
134 D2S2215a 9 9 2.84
137 D2S1260 9 9 5.36
141 D2S112 3 3 4.95
142 D2S2219 10 10 3.18
145 D2S1334 11 11 4.59
147 D2S2288 1 6 3.06
152 D2S151 15 11 6.34
NOTE.— The two intervals in which the disease-linked alleles in
families YH1 and P2 are identical are shown in boxes. Genealogy
investigations confirmed that the two families are related, and themost
likely explanation for the interval between D2S1890 and D2S100, in
which the disease-linked alleles differ, is a historic double recombi-
nation between the two families.
a Recombinants at this marker in family YH1 (individuals IV:3 and
V:7) define the minimal dHMN-VII interval.
investigate this further, 30 markers from the dHMN-VII
interval were analyzed in both families (table 3). Iden-
tical disease-segregating alleles were seen in both families
at 22 markers, which supports our conjecture of a com-
mon ancestral origin for the two families. Genealogy
investigations subsequently confirmed that the families
are indeed related, with individual I:1 in family YH1
being the uncle of individual I:2 in family P2. LOD
scores calculated with the combined pedigree generated
a maximum two-point LOD score of 6.63 at D2S275
and a maximum three-point LOD score of 7.49 at
D2S274.
There were two separate regions in the disease-asso-
ciated haplotypes in families YH1 and P2, at which the
segregating alleles were identical in both families (table
3). The centromeric interval, demonstrating allelic as-
sociation in the two families, was between D2S2216 and
D2S160. The telomeric interval, showing allelic associ-
ation, was between D2S2970 and D2S2288. The mul-
tipoint LOD scores were strongly positive within both
of these intervals (fig. 3). Between the two regions there
was a 7-cM interval, flanked by D2S1890 and D2S100,
in which the disease-segregating alleles differed in the
two families (table 3) and the multipoint LOD scores
were much lower (fig. 3). The location of the markers
analyzed within the D2S1890–D2S100 interval could be
confidently assigned by reference to the genetic radiation
hybrid and physical maps of chromosome 2q14, and
they clearly bisect the disease-associated haplotype that
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Figure 1 Haplotypes for 12 markers from chromosome 2q14 from members of family YH1. Blackened symbols, individuals affected
with dHMN-VII. Unblackened symbols, unaffected individuals. Boxes around marker alleles indicate disease haplotypes present in the affected
individuals. Boxed alleles in unaffected individuals IV:3 and V:7 define the minimum interval encompassing the dHMN-VII gene to the region
between D2S2264 and D2S2215.
segregates in the two families. It is therefore most likely
that a double recombination event has occurred between
the two families, with one recombination event occur-
ring between markers D2S1890 and D2S160 and the
other between D2S2970 and D2S100. The data strongly
suggest that the dHMN-VII gene does not lie between
markers D2S160 and D2S2970.
The combined linkage, allelic association, and recom-
binant data from families YH1 and P2 localize the
dHMN-VII predisposition gene either to the 8-cM re-
gion flanked by D2S2264 and D2S160 or the 7-cM re-
gion flanked by D2S2970 and D2S2215. The gene has
been designated DHMNVP (distal hereditary motor
neuronopathy with vocal cord paralysis).
No genes for distal hereditary motor neuronopathy
have been identified, and it is therefore difficult to predict
what the function of DHMNVP might be. However, it
is highly likely that the gene is expressed in the spinal
cord. Two possible candidates for the dHMN-VII gene
are Engrailed-1 (EN1) and the neuronal PAS domain
protein-2 gene (NPAS-2), both of which encode tran-
scription factors that are strongly expressed in the spinal
cord of mice (Davis et al. 1988; Zhou et al. 1997). EN1
is a homeobox-containing gene that has been implicated
in the regulation of axon pathfinding by association in-
terneurons that project to motor neurons in the spinal
cord (Saueressig et al. 1999). To confirm that EN1 is
within the dHMN-VII interval(s), a dinucleotide repeat
located 3 kb 5′ of EN1 was identified, and amplifying
primers were designed and optimized (table 3). The re-
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Figure 2 Haplotypes for 12 markers from chromosome 2q14 from members of family P2. Data from at-risk individuals aged !20 years
have been omitted. Boxes around marker alleles indicate disease haplotypes present in the affected individuals.
Table 4
Primer Pairs for PCR Amplification of EN1 Repeat and Polyalanine Tract
PRIMER (5′r3′)
Forward Reverse
Dinucleotide repeat GACTAGTGGGGCTGACTTGG GCTCAGCGGTCTTGAAGAGT
Polyalanine tract GCAGGTAGAGACCCTGTCCA AAGTAGGATAGCCGGGTTGC
peat was amplified in families YH1 and P2, and a single
allele segregated with the disease in both families, gen-
erating a two-point LOD score of 3.58 (data not shown).
The first exon of EN1 contains an imperfect poly-
alanine repeat of the form alanine(10)-valine-alanine(9).
Pathogenic expansions of short polyalanine tracts have
been reported in a number of disorders, including ocu-
lopharyngeal muscular dystrophy, in which expansions
of alanine(6) to alanine(8-13) in the PABP2 gene have
been identified (Brais et al. 1998). Primers amplifying
the polyalanine tract in EN1 were designed (table 4) and
analyzed in one affected and one unaffected individual
from families YH1 and P2. No alteration in the size of
the amplified fragment was identified in the two indi-
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Figure 3 Multipoint LOD score for combined dHMN-VII
pedigree.
viduals affected by dHMN-VII compared with the con-
trols (data not shown). Thus, expansion of the EN1
polyalanine tract is not responsible for dHMN-VII.
However, intragenic EN1 mutations were not investi-
gated and may be responsible for dHMN-VII.
Hereditary motor and sensory neuropathy type IIC
(HMSN-IIC [MIM 158580]) shows considerable over-
lap with dHMN-VII. HMSN-IIC is an autosomal dom-
inant disorder characterized by motor and sensory in-
volvement of the limbs, with progressive weakness of
the vocal cords, diaphragm, and intercostal muscles
(Dyck et al. 1994; Yoshioka et al. 1996; Donaghy et al.
1999). The distinguishing feature of HMSN-IIC is sen-
sory involvement, which is not seen in dHMN-VII. The
gene for HMSN-IIC has not been localized, but it has
been suggested that HMSN-IIC and dHMN-VII may be
allelic disorders that are caused by mutations of the same
gene (Dyck et al. 1994). There is a precedent for such
allelism, as dHMN-V and HMSN-IID have both been
linked to chromosome 7p15 (Christodoulou et al. 1995;
Ionasescu et al. 1996). Moreover, a kindred in which
both phenotypes segregate in association with the same
chromosome 7p15 haplotype has been reported (Sam-
buughin et al. 1998). Linkage analyses at chromosome
2q14 in HMSN-IIC pedigrees should determine whether
or not the condition is likely to be due to the dHMN-
VII gene on chromosome 2q14.
Other conditions with phenotypic overlap with
dHMN-VII would also be worth examining for linkage
to chromosome 2q14. A family with dHMN, vocal cord
paralysis, and sensorineural deafness has been reported;
these features may be the result of aDHMNVPmutation
(Bolthauser et al. 1989). However, a family with some
individuals having CMT, sensorineural deafness, and vo-
cal cord paralysis has been described, in which a path-
ogenic PMP22 point mutation was identified (Kovach
et al. 1999). Thus, genetic heterogeneity in conditions
with peroneal muscular atrophy and vocal cord paralysis
is likely to exist.
The identification of a further disease locus for dHMN
adds to our growing knowledge of the disease loci in-
volved in this subset of peroneal muscular atrophy. Iso-
lation of genes altered in dHMN will not only improve
our understanding of these disorders but will also help
to clarify the relationship between dHMN and HMSN.
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